Portfolio management is changing to place more emphasis on the risk/benefit ratio. Since most new molecular entities can treat more than one disease, companies may select for initial development diseases which have a greater tolerance for potential risks.

Learning Objectives:
Describe a risk/reward approach to portfolio management
Discuss how recent changes in risk/benefit perceptions by regulators are changing portfolio strategies
Assess how greater expectations for safety data may influence choice of indication for new molecular entities.